The Global Health Innovation Network (GHIN) is the first initiative launched under the Sweden-Singapore bilateral Memorandum of Understanding on health innovation collaboration, signed during the Swedish state visit to Singapore in November 2024.
GHIN is a Sweden-Singapore partnership framework dedicated to advancing breakthrough technologies and solutions in health through structured collaboration between the two nations. GHIN's mission is to identify, implement, and scale health innovations that address pressing clinical needs in the two healthcare systems, with a strong emphasis on practical implementation - often the greatest challenge in health innovation globally.
Current GHIN focus areas:
- Precision Medicine
- AI in Health
- Sustainability in Health
- 5G (and beyond) in Health (including Hospital@Home).
GHIN is being developed step by step, starting with building mutual understanding of the Swedish and Singaporean healthcare systems. While the two systems share many similarities, there are also important differences that must be acknowledged to ensure the successful implementation of joint projects. The aim is to build a strong foundation for tangible partnership opportunities.
Today, more than 30 people are engaged in the initiative, including 14 clinicians from the two partner hospitals. The first set of collaborative projects is now being finalized and will be implemented simultaneously at both hospitals - accelerating learning, testing solutions in two distinct contexts, and enhancing their global relevance and scalability. The first initiatives are set to kick off in November 2025.
GHIN has been established as an open innovation ecosystem, welcoming collaborations with Swedish, Singaporean, and international stakeholders. Still in its early stages, the network aims to grow with more partners in the years ahead, amplifying collective efforts to create more effective healthcare solutions globally.
GHIN Founding Partners
Sahlgrenska University Hospital in Gothenburg is Sweden's largest hospital and one of the largest university hospitals in Europe and focuses on patient care, national highly specialized care, education, research and innovation. Sahlgrenska University Hospital has the expertise to perform the most advanced treatments and procedures that today's medical developments allow. At Sahlgrenska University Hospital, the inhabitants of western Sweden are close to advanced healthcare that is also in demand nationally and internationally.
The National University Health System (NUHS) aims to transform how illness is prevented and managed by discovering causes of disease, development of more effective treatments through collaborative multidisciplinary research and clinical trials, and creation of better technologies and care delivery systems in partnership with others who share the same values and vision.
Institutions in the NUHS Group include the National University Hospital, Ng Teng Fong General Hospital, Jurong Community Hospital and Alexandra Hospital; three National Specialty Centres - National University Cancer Institute, Singapore (NCIS), National University Heart Centre, Singapore (NUHCS) and National University Centre for Oral Health, Singapore (NUCOHS); the National University Polyclinics (NUP); Jurong Medical Centre; and three NUS health sciences schools – NUS Yong Loo Lin School of Medicine (including the Alice Lee Centre for Nursing Studies), NUS Faculty of Dentistry and NUS Saw Swee Hock School of Public Health.
With member institutions under a common governance structure, NUHS creates synergies for the advancement of health by integrating patient care, health science education and biomedical research.
As a Regional Health System, NUHS works closely with health and social care partners across Singapore to develop and implement programmes that contribute to a healthy and engaged population in the Western part of Singapore.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
Ericsson’s high-performing, programmable networks provide connectivity for billions of people every day. For nearly 150 years, we’ve been pioneers in creating technology for communication. We offer mobile communication and connectivity solutions for service providers and enterprises. Together with our customers and partners, we make the digital world of tomorrow a reality.
We are business developers with a unique mandate to help Swedish companies grow global sales and international companies invest and expand in Sweden.
Business Sweden is jointly owned by the Swedish state and the Swedish business sector with a mandate and a mission to help international companies gain access to the Swedish market and help domestic ones utilise it as a platform for expansion. Our clients range from start-ups via small- and medium sized businesses to multinational enterprises – with tailor-made services catering to all of these segments.